Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Year: 2011
Type: article
Source: Diabetes Obesity and Metabolism
Authors: R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D. E. Sharp, R. A. Bakker, M. Mark, T. Klein, P. Eickelmann
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Boehringer Ingelheim
OpenAlex ID: W2134855422